Copy Link Print Information

Emavusertib phosphate

(Synonyms: CA-4948 phosphate)
7 Cited Publications
Avis client

Based on 7 publication(s) in Google Scholar

Emavusertib phosphate (CA-4948 phosphate) is the phosphate salt form of Emavusertib (HY-135317). Emavusertib phosphate is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib phosphate inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib phosphate exhibits antitumor activity in mouse model.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • CAS No.: 2376399-38-9
  • Formule: C24H28N7O9P
  • Masse moléculaire:589.49
  • Stockage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Emavusertib phosphate Chemical Structure
    Emavusertib phosphate Chemical Structure
  • Experimental Validation Results for Emavusertib phosphate
  • Experimental Validation Results for Emavusertib phosphate
  • Experimental Validation Results for Emavusertib phosphate
  • Experimental Validation Results for Emavusertib phosphate
  • Experimental Validation Results for Emavusertib phosphate
  • Experimental Validation Results for Emavusertib phosphate
CAS No.: 2376399-38-9
Size
Prix
Stock
Quantité
Amount: USD 0.00
Please select quantity
or
or

* Veuillez sélectionner la quantité avant d'ajouter des articles.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Emavusertib phosphate:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Trouvez votre distributeur local Your local distributor: Hycultec GmbHHycultec
  • Activité biologique
  • Chemical Information
  • Pureté et documentation
  • Références
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Emavusertib phosphate

More
Customer Validation & Images
In Vivo Efficacy StudyBio/Physico-chemical AssayCell Proliferation/Viability AssayIHCWB
  • Cell Proliferation/Viability Assay
  • WB
  • In Vivo Efficacy Study
  • IHC
  • Bio/Physico-chemical Assay
  • WB

Voir tous les produits spécifiques à Isoform IRAK

More

Voir tous les produits spécifiques à Isoform NF-κB

More
Keywords
MOQ
Minimum order quantity
100 mg

Obtenir un devis En stock

Other size
Obtenir un devis
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Enregistrer
Sign in to MedChemExpress
Enregistrer un nouveau compte

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Emavusertib phosphate Chemical Structure
    Emavusertib phosphate Chemical Structure
    1/16
  • 1/16

    Emavusertib phosphate purchased from MedChemExpress. Usage Cited in: Leukemia. 2025 Sep;39(9):2163-2173. [Abstract]

    Customer Validation
     Cell viability was determined in THP1 and HL60 cells cultured with 10 µM CA-4948 (Emavusertib) or in OCI-AML3 and K562 cultured with 1 µM CA-4948 or vehicle (n = 4) for 14 days and then treated with CC-885 (n = 4).

  • 1/16

    Emavusertib phosphate purchased from MedChemExpress. Usage Cited in: Leukemia. 2025 Sep;39(9):2163-2173. [Abstract]

    Customer Validation
     Immunoblots for c-MYC in the patient-derived AML samples (AML1794, AML1714) cultured with CA-4948 (Emavusertib) (10 µM) or vehicle for 14 days and then treated with CC-885 (50 nM) for 4 h.

  • 1/16

    Emavusertib phosphate purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 Sep 24;44(10):116347. [Abstract]

    Customer Validation
     Harvested tumor weights by treatment condition (n = 8 per condition).Tumor growth studies demonstrated statistically significant inhibition with both CA-4948 (Emavusertib) (50 mg/kg; oral gavage; once daily) alone and ICB alone.

  • 1/16

    Emavusertib phosphate purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 Sep 24;44(10):116347. [Abstract]

    Customer Validation
     H&E and trichrome staining of tumors by treatment condition (Emavusertib (50 mg/kg; oral gavage; once daily), ect.) at 10× magnification. The scale bar represents 100 μm.

  • 1/16

    Emavusertib phosphate purchased from MedChemExpress. Usage Cited in: Blood. 2023 Sep 14;142(11):989-1007. [Abstract]

    Customer Validation
     IC50 curves for CA-4948 (Emavusertib) (0.01-10000 nM; 24 h) and PF-06650833 in an assay measuring NF-kB activity upon TLR2 stimulation with PAM3CSK4 in THP1 NF-kB reporter cells.

  • 1/16

    Emavusertib phosphate purchased from MedChemExpress. Usage Cited in: Blood. 2023 Sep 14;142(11):989-1007. [Abstract]

    Customer Validation
     Immunoblots for phospho-IRAK1, total IRAK1, IRAK2, and IRAK4 in MDSL and AML (1714) treated for 24 hours with CA-4948 (Emavusertib) (10 μM). The results showed that treatment with CA-4948 resulted in increased IRAK1 phosphorylation.

  • Emavusertib phosphate